AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CYCLOPHARM LTD

1.155

-0.085-6.85%

Volume:66.23K

Turnover:77.95K

Market Cap:128.36M

PE:-9.00

High:1.250

Open:1.250

Low:1.150

Close:1.240

Loading ...

Overview Company News Filings

BUZZ-Australia's Cyclopharm gains on US medical technology supply deal

ASX Market Open: Booze-fuelled S&P 500 correction to see Oz bourse close Week 11 red | March 14, 2025

The Market Herald

ASX Alert-Cyc Signs 5-Year Agreement With USA Veterans Administration-Cyc.ax

THOMSON REUTERS

With A 38% Price Drop For Cyclopharm Limited (ASX:CYC) You'll Still Get What You Pay For

Simply Wall St.

Cyclopharm Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

BRIEF-Cyclopharm Reports FY Net Loss Attributable A$13.2 Mln

BUZZ-Australia's Cyclopharm falls on wider HY loss

Cyclopharm - FY Net Loss Attributable a$13.2 Mln

THOMSON REUTERS

Here's Why We're Not Too Worried About Cyclopharm's (ASX:CYC) Cash Burn Situation

Simply Wall St.

When Can We Expect A Profit From Cyclopharm Limited (ASX:CYC)?

Simply Wall St.

Cyclopharm secures major US deal to deploy Technegas products across HCA network

BRIEF-Cyclopharm Says Co Signs US National Agreement With HCA For Technegas

BUZZ-Australia's Cyclopharm soars on diagnostic tech deployment contract

Cyclopharm Signs Agreement With US Healthcare Services Provider; Shares Up 13%

MT Newswires Live

Cyclopharm Ltd -Signs US National Agreement With HCA for Technegas

THOMSON REUTERS

"A great market for stock pickers" and 5 ASX picks from IML's Lucas Goode

5 ASX stocks to own as the market keeps rallying

3 ASX All Ords shares leading the charge in 2025

Cyclopharm Limited (ASX:CYC) Not Flying Under The Radar

Simply Wall St.

The #1 growth stocks set to explode in 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYC.AU\",,,,,undefined,":{"symbol":"CYC.AU","market":"AU","secType":"STK","nameCN":"CYCLOPHARM LTD","latestPrice":1.155,"timestamp":1747203120000,"preClose":1.24,"halted":0,"volume":66228,"delay":0,"nameEN":"CYCLOPHARM LTD","floatShares":56552486,"shares":111136850,"eps":-0.1283,"marketStatus":"Not Yet Opened","change":-0.085,"latestTime":"05-14 16:12:00 AEST","open":1.25,"high":1.25,"low":1.15,"amount":77945,"amplitude":0.080645,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1283,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747267200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.24,"openAndCloseTimeList":[[1747180800000,1747202400000]],"volumeRatio":0.6439869086457919,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYC.AU\",,,,,undefined,":{"symbol":"CYC.AU","floatShares":56552486,"roa":"-16.80%","roe":"-35.20%","lyrEps":-0.128254,"volumeRatio":0.6439869086457919,"shares":111136850,"dividePrice":0,"high":1.25,"amplitude":0.080645,"preClose":1.24,"low":1.15,"week52Low":1.025,"pbRate":"3.00","psRate":"4.66","week52High":2.5,"institutionHeld":0,"latestPrice":1.155,"eps":-0.1283,"divideRate":0,"volume":66228,"delay":0,"ttmEps":-0.1283,"open":1.25,"prevYearClose":1.585,"prevWeekClose":1.35,"prevMonthClose":1.17,"prevQuarterClose":1.15,"fiveDayClose":1.27,"twentyDayClose":1.105,"sixtyDayClose":1.9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519489167","title":"BUZZ-Australia's Cyclopharm gains on US medical technology supply deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2519489167","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519489167?lang=en_us&edition=fundamental","pubTime":"2025-03-14 08:21","pubTimestamp":1741911719,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cyclopharm gains on US medical technology supply deal** Shares of Cyclopharm CYC.AX rise 6.6% to A$1.525, their highest level since February 27** Radiopharmaceutical co says its signe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL4N3PX00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2519289853","title":"ASX Market Open: Booze-fuelled S&P 500 correction to see Oz bourse close Week 11 red | March 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519289853","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519289853?lang=en_us&edition=fundamental","pubTime":"2025-03-14 05:37","pubTimestamp":1741901820,"startTime":"0","endTime":"0","summary":"In a dour end to what’s been a red-washed Week 11, early morning ASX 200 futures are pointing to a 0.2% decline – to around 7,734 points today – after Trump’s trade war found a fiery new battleground: Global alcohol sales.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The back and forth hit the S&P 500 hard; it closed at its lowest since September.Back home, Rio Tinto  has agreed to buy 90% of the output from two solar and battery projects in central Queensland now being built by Edify Energy; a move in line with its pledge to run on clean energy by 2030.Matsa Resources  will also be one discussed on HotCopper forums today after the gold miner fired up its drills at Fortitude North Lake Carey again. Both continued continuity tests and an extension hunt are on the cards.Cyclopharm  has upgraded its U.S. Veterans Administration deal to a five-year pledge.That’s Market Open, I’m Isaac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-booze-fuelled-sp-500-correction-to-see-oz-bourse-close-week-11-red-march-14-2025-2025-03-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4559","BK4588","IVV","BK4550","BK7104","BK7506","BK7095","RLT.AU","OEF","RIO.AU","BK4581","BK4534","OEX","MAT.AU","SDS","SH",".SPX","ESmain","SPXU","VOO","BK4504","CYC.AU","SSO","BK7007","BK7142","BK7507","SPY","BK4585","BK7511"],"gpt_icon":1},{"id":"2519862711","title":"ASX Alert-Cyc Signs 5-Year Agreement With USA Veterans Administration-Cyc.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2519862711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519862711?lang=en_us&edition=fundamental","pubTime":"2025-03-14 05:20","pubTimestamp":1741900841,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW1D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2518372707","title":"With A 38% Price Drop For Cyclopharm Limited (ASX:CYC) You'll Still Get What You Pay For","url":"https://stock-news.laohu8.com/highlight/detail?id=2518372707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518372707?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:50","pubTimestamp":1741639820,"startTime":"0","endTime":"0","summary":"Cyclopharm Limited ( ASX:CYC ) shares have had a horrible month, losing 38% after a relatively good period beforehand...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cyc/cyclopharm-shares/news/with-a-38-price-drop-for-cyclopharm-limited-asxcyc-youll-sti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2514862686","title":"Cyclopharm Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862686","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862686?lang=en_us&edition=fundamental","pubTime":"2025-02-27 04:03","pubTimestamp":1740600222,"startTime":"0","endTime":"0","summary":"ASX:CYC Earnings and Revenue History February 26th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 1.5%. Earnings per share  also missed analyst estimates by 14%.Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.The company's shares are down 25% from a week ago.We should say that we've discovered 2 warning signs for Cyclopharm that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cyclopharm-full-2024-earnings-misses-200342759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CYC.AU"],"gpt_icon":0},{"id":"2514052089","title":"BRIEF-Cyclopharm Reports FY Net Loss Attributable A$13.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514052089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514052089?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:32","pubTimestamp":1740447120,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Reports FY Net Loss Attributable A$13.2 MlnFeb 25 (Reuters) - Cyclopharm Ltd CYC.AX:FY NET LOSS ATTRIBUTABLE A$13.2 MILLIONFY REVENUES FROM ORDINARY ACTIVITIES A$27.6 MILLIONFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2514108520","title":"BUZZ-Australia's Cyclopharm falls on wider HY loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2514108520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514108520?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:49","pubTimestamp":1740444572,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cyclopharm falls on wider HY loss** Shares of Cyclopharm CYC.AX fall 18.4% to A$1.550, their lowest level since December 30** Stock on track for sharpest one-day pct drop since late-J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2514054897","title":"Cyclopharm - FY Net Loss Attributable a$13.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514054897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514054897?lang=en_us&edition=fundamental","pubTime":"2025-02-25 05:05","pubTimestamp":1740431103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2512149967","title":"Here's Why We're Not Too Worried About Cyclopharm's (ASX:CYC) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512149967","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512149967?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:14","pubTimestamp":1739909673,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cyc/cyclopharm-shares/news/heres-why-were-not-too-worried-about-cyclopharms-asxcyc-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2506511549","title":"When Can We Expect A Profit From Cyclopharm Limited (ASX:CYC)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506511549","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506511549?lang=en_us&edition=fundamental","pubTime":"2025-01-28 12:49","pubTimestamp":1738039788,"startTime":"0","endTime":"0","summary":"Cyclopharm Limited ( ASX:CYC ) is possibly approaching a major achievement in its business, so we would like to shine...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cyc/cyclopharm-shares/news/when-can-we-expect-a-profit-from-cyclopharm-limited-asxcyc-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2505055033","title":"Cyclopharm secures major US deal to deploy Technegas products across HCA network","url":"https://stock-news.laohu8.com/highlight/detail?id=2505055033","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505055033?lang=en_us&edition=fundamental","pubTime":"2025-01-23 10:55","pubTimestamp":1737600936,"startTime":"0","endTime":"0","summary":"The three-year contract marks a significant milestone for the company, as HCA operates one of the most comprehensive medical networks in the US.Technegas is already the preferred agent of choice in 65 countries outside the US for diagnosing lung conditions including pulmonary embolism, hypertension and chronic obstructive pulmonary disease.HCA’s operations encompass more than 180 hospitals and approximately 2,400 sites of care across 20 American states.The deal’s broad-based format will allow it to bypass the need for individual site contract negotiations and enhance the efficiency of deployment.It also clears the way for discussions with HCA-affiliated company HealthTrust Purchasing Group, which serves as the contracting and purchasing arm for an additional network of more than 1,800 hospitals across the US.Cyclopharm chief executive officer James McBrayer said the new contract reflected commercial demand for the company’s technology.“We are thrilled to partner with HCA Healthcare to ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Cyclopharm-ASX-CYC-Technegas-HCA-Healthcare-US-agreement.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Cyclopharm-ASX-CYC-Technegas-HCA-Healthcare-US-agreement.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/cyclopharm-major-us-deal-deploy-technegas-hca-network/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7007","LU0878866978.SGD","HCA","LU1150488218.USD","SG9999014039.USD","BK4504","CYC.AU","SG9999014021.USD","LU0868494617.USD","IE00B3S45H60.SGD","LU1489326972.SGD","LU0029864427.USD","LU0130102774.USD","LU0187121727.USD","LU1084165304.USD","LU1267930573.SGD","LU0648001328.SGD","IE00B775SV38.USD","LU0985489474.SGD","LU0708994859.HKD","LU1267930490.SGD","SG9999014005.SGD","LU0980610538.SGD","LU1201861249.SGD","BK4588","LU0211328371.USD","LU0128525929.USD","LU0068578508.USD","LU0310800379.SGD","LU0211327993.USD","BK4185","BK4585","LU2244417387.USD","LU0114720955.EUR","LU0203347892.USD","LU0882574055.USD","LU1119994496.HKD","LU1261432733.SGD","SG9999014013.SGD","LU0310799852.SGD","LU0203345920.USD","LU1150488135.SGD","LU0433182093.SGD"],"gpt_icon":0},{"id":"2505908409","title":"BRIEF-Cyclopharm Says Co Signs US National Agreement With HCA For Technegas","url":"https://stock-news.laohu8.com/highlight/detail?id=2505908409","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505908409?lang=en_us&edition=fundamental","pubTime":"2025-01-23 09:21","pubTimestamp":1737595311,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Says Co Signs US National Agreement With HCA For TechnegasJan 23 (Reuters) - Cyclopharm CYC.AX:SIGNS US NATIONAL AGREEMENT WITH HCA FOR TECHNEGASFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nFWN3OI14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2505308900","title":"BUZZ-Australia's Cyclopharm soars on diagnostic tech deployment contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2505308900","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505308900?lang=en_us&edition=fundamental","pubTime":"2025-01-23 08:45","pubTimestamp":1737593125,"startTime":"0","endTime":"0","summary":"** Shares of Cyclopharm    up 17.2% at A$2.38   ** Stock rises as much as 23.2% to A$2.5 in early trade, hitting its highest level since Oct 16, 2023   ** Radiopharmaceutical firm signs contract with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU1150488135.SGD","LU0211328371.USD","BK4588","LU1119994496.HKD","LU2244417387.USD","LU1084165304.USD","LU0211327993.USD","LU0203345920.USD","LU0980610538.SGD","LU0187121727.USD","LU0868494617.USD","LU1261432733.SGD","LU0882574055.USD","LU0310799852.SGD","LU0114720955.EUR","LU0648001328.SGD","BK4185","SG9999014005.SGD","IE00B775SV38.USD","SG9999014021.USD","LU1201861249.SGD","LU0068578508.USD","LU0878866978.SGD","CYC.AU","IE00B3S45H60.SGD","SG9999014039.USD","LU0130102774.USD","HCA","LU1267930490.SGD","BK4585","LU0203347892.USD","LU0128525929.USD","BK7007","LU1150488218.USD","LU0029864427.USD","LU1489326972.SGD","SG9999014013.SGD","LU1267930573.SGD","LU0985489474.SGD","BK4504","LU0708994859.HKD","LU0433182093.SGD"],"gpt_icon":0},{"id":"2505105088","title":"Cyclopharm Signs Agreement With US Healthcare Services Provider; Shares Up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505105088","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505105088?lang=en_us&edition=fundamental","pubTime":"2025-01-23 07:26","pubTimestamp":1737588419,"startTime":"0","endTime":"0","summary":"Cyclopharm  entered an agreement with Hospital Corporation of America Healthcare  to deploy its Technegas technology to the healthcare services provider's nuclear medicine departments, according to a Thursday filing with the Australian bourse.The deal, initiated by HCA after multiple of its sites expressed interest, streamlines the process by bypassing individual contract negotiations, the filing said.Technegas is used to diagnose lung conditions like pulmonary embolism, chronic obstructive pulmonary disease, and hypertension, the filing added.The agreement also opens doors to collaboration with HealthTrust Purchasing Group, HCA's group purchasing organization, the company said.Cyclopharm will now engage directly with individual HCA locations to roll out the technology, the company added.The company's shares surged almost 13% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0203347892.USD","LU0068578508.USD","LU0310799852.SGD","HCAR","LU1489326972.SGD","LU1084165304.USD","LU1267930573.SGD","BK7007","HCA","LU2244417387.USD","LU0211327993.USD","LU0433182093.SGD","LU1201861249.SGD","LU1261432733.SGD","LU0882574055.USD","LU0985489474.SGD","LU0029864427.USD","BK4504","HCSG","IE00B3S45H60.SGD","LU0187121727.USD","LU1267930490.SGD","LU0130102774.USD","LU0128525929.USD","BK4588","SG9999014021.USD","BK4185","LU1119994496.HKD","LU1150488218.USD","SG9999014013.SGD","LU0708994859.HKD","LU0114720955.EUR","LU0980610538.SGD","LU0878866978.SGD","LU0211328371.USD","BK4585","LU1150488135.SGD","SG9999014005.SGD","LU0310800379.SGD","SG9999014039.USD","LU0203345920.USD","LU0648001328.SGD","LU0868494617.USD","IE00B775SV38.USD","CYC.AU","BK4137"],"gpt_icon":0},{"id":"2505706710","title":"Cyclopharm Ltd -Signs US National Agreement With HCA for Technegas","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706710?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:20","pubTimestamp":1737580806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2505038254","title":"\"A great market for stock pickers\" and 5 ASX picks from IML's Lucas Goode","url":"https://stock-news.laohu8.com/highlight/detail?id=2505038254","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505038254?lang=en_us&edition=fundamental","pubTime":"2025-01-21 08:30","pubTimestamp":1737419413,"startTime":"0","endTime":"0","summary":"Note: This interview was taped Tuesday 10 December 2024.Whilst IML's Lucas Goode has a positive outlook for markets in 2025, he's not quite prepared to say that he's outright bullish.Doing so, in his words, \"would imply that I think the overall market's going to rip 20% again, and that's not necessarily the case\".Goode adds that the rally we've seen in recent years has been quite narrow and has the potential to broaden out which would create a \"great market for stock pickers, those willing to return to fundamentals\".Sector set for a breakout and the stock to play it: Sector: Defence, stock: Austal . We think they're going to have an order book approaching $30 billion by the end of next year, and yet the company trades at a material discount to its net asset backing. I mean it's just a clear mispricing to us. We think it's one of the best opportunities on the ASX\".Contrarian call that may just surge in 2025 -Kelsian Group . A stock on the avoid list for 2025 - NextDC . A sleep at night ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/a-great-market-for-stock-pickers-and-5-asx-picks-from-iml-s-lucas-goode","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/a-great-market-for-stock-pickers-and-5-asx-picks-from-iml-s-lucas-goode","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7043","NXT.AU","BK7115","XJO.AU","BK7158","ASB.AU","XAO.AU","LEI","CCL.AU","BK7503","BK7125","BK7161","CYC.AU","XKO.AU","KLS.AU","BK7007"],"gpt_icon":0},{"id":"2503399442","title":"5 ASX stocks to own as the market keeps rallying","url":"https://stock-news.laohu8.com/highlight/detail?id=2503399442","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503399442?lang=en_us&edition=fundamental","pubTime":"2025-01-13 04:00","pubTimestamp":1736712015,"startTime":"0","endTime":"0","summary":"remains constructive. Recession fears have now receded, corporate earnings are forecast to grow, interest rates are set to moderate, and the narrow rally we saw in 2024 is set to broaden in 2025.In the first phase of a rate-cutting cycle, revenues begin to recover on reduced cost bases, which combined deliver expanded operating margins and profitability.We expect 2025 to be a good year for equity investors.  We continue to see value in several sectors,Here are five stocks that are well-positioned to outperform in 2025:. Importantly, the company has also secured funding for the product's use in the US via Transitional Pass Through  reimbursement. As a result,Cyclopharm expects the size of the US nuclear medicine PE market to double from US$90M to US$180M within the next 3-5 years.As a result, we expect strong earnings growth and improving profitability to drive share price outperformance over the long term. A strong 1H FY25 recently de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-asx-stocks-to-own-as-the-market-keeps-rallying","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-asx-stocks-to-own-as-the-market-keeps-rallying","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["XKO.AU","ZIP","BK4080","EHL.AU","SKS.AU","ROIC","ZIP.AU","BK4231","BK7007","BK4539","BK4077","BK7501","FPH.AU","BK7093","CYC.AU","BK7023","XJO.AU","BK7031","XAO.AU"],"gpt_icon":0},{"id":"2502009293","title":"3 ASX All Ords shares leading the charge in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502009293","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502009293?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:55","pubTimestamp":1736477701,"startTime":"0","endTime":"0","summary":"Although under pressure today, the All Ordinaries Index is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains. At market close yesterday, these three companies were leading the charge higher in the nascent new year. You'll also notice a decided trend in the sector they operate in. Which soaring ASX All Ords shares are we talking about?) The EBR Systems share price closed out 2024 at $1.025. In Friday afternoon trade, shares are changing hands for $1.40 apiece. That sees this ASX All Ords stock up 36.6% already in the new year. On Monday, the company, which is developing the world's only wireless cardiac pacing device for heart failure , reported that the US Food and Drug Administration  had scheduled the manufacturing Pre-Approval Inspection  to commence on 14 January. \"This significant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-all-ords-shares-leading-the-charge-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PAI.AU","CYC.AU","BK7007","XKO.AU","BK7508","XAO.AU","IMU.AU","EBR.AU","PAI","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2501248179","title":"Cyclopharm Limited (ASX:CYC) Not Flying Under The Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2501248179","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501248179?lang=en_us&edition=fundamental","pubTime":"2025-01-07 04:14","pubTimestamp":1736194451,"startTime":"0","endTime":"0","summary":"When close to half the companies in the Medical Equipment industry in Australia have price-to-sales ratios (or \"P/S...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cyc/cyclopharm-shares/news/cyclopharm-limited-asxcyc-not-flying-under-the-radar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2501449276","title":"The #1 growth stocks set to explode in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501449276","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501449276?lang=en_us&edition=fundamental","pubTime":"2025-01-06 04:00","pubTimestamp":1736107237,"startTime":"0","endTime":"0","summary":"You can watch the video by clicking the player, listen to the podcast, or read an edited transcript below. These interviews were filmed on Tuesday, 10 December 2023.The name Thomas Rowe Price Junior should have been consigned to the investing scrap heap.Born in 1898, Price’s career was just hitting its stride as the Great Depression hit and hit hard. At the time, he was the head of investment for the broking firm MacKubin, Legg and Co., but instead of developing great hate for markets, he fell even more in love with them.That inspired him to start T. Rowe Price and Associates in 1937, with a then-revolutionary focus on growth investing.His guiding philosophy was that by investing in well-managed companies operating in deep pools of opportunity, he could generate returns ahead of inflation and the overall economy.It’s a philosophy that would earn Price the moniker the “Father of growth investing”. T. Rowe Price still operates to this day and manages around US$1.6 trillion globally.Proba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-1-growth-stocks-set-to-explode-in-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-1-growth-stocks-set-to-explode-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU1961090484.USD","LU0143863784.USD","VNDA","LU0594300419.USD","LU0572944931.SGD","360.AU","LU0650527681.SGD","BK4585","TCOM","LU2152927971.USD","LU1023057109.AUD","ARR","CORZ","IE00B5MMRT66.SGD","BK7095","LU0359202008.SGD","BK7043","LU0359201612.USD","LU0048580855.USD","BK4526","BOE.AU","BK4139","PGC.AU","LU0593848301.USD","BK4116","BK7166","LU0828237510.HKD","QOR.AU","ARR.AU","ZIP.AU","LU0561508036.HKD","LU0370786039.SGD","IE00BPRC5H50.USD","BK4534","BK4142","NXT.AU","LU0737861772.HKD","DGT.AU","SIG.AU","LU0228659784.USD","BK7007","CYC.AU","TNE.AU","LU0348825331.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU2399975544.HKD","LU0359201885.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYC.AU\",params:#limit:5,,,undefined,":[{"date":"2023-09-01","symbol":"CYC.AU","amount":0.005,"announcedDate":"2023-08-22","type":"dividend","market":"AU","newRecordDate":"2023-09-04","defaultRemindTime":1693526400000,"name":"Cyclopharm Ltd","recordDate":"2023-09-11","payableDate":"2023-09-04","currency":"AUD","dateTimestamp":1693490400000,"payDate":"2023-09-11"},{"market":"AU","date":"2023-03-27","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1679871600000,"name":"Cyclopharm Ltd","recordDate":"2023-04-04","payableDate":"2023-03-28","currency":"AUD","type":"dividend","dateTimestamp":1679835600000},{"market":"AU","date":"2022-09-02","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1662076800000,"name":"Cyclopharm Ltd","recordDate":"2022-09-12","payableDate":"2022-09-05","currency":"AUD","type":"dividend","dateTimestamp":1662040800000},{"market":"AU","date":"2022-04-04","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1649030400000,"name":"Cyclopharm Ltd","recordDate":"2022-04-12","payableDate":"2022-04-05","currency":"AUD","type":"dividend","dateTimestamp":1648994400000},{"market":"AU","date":"2021-09-03","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1630627200000,"name":"Cyclopharm Ltd","recordDate":"2021-09-13","payableDate":"2021-09-06","currency":"AUD","type":"dividend","dateTimestamp":1630591200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYC.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-04","recordDate":"2020-09-07","paymentDate":"2020-09-14","value":0.005,"currency":"AUD"},{"executeDate":"2021-04-01","recordDate":"2021-04-06","paymentDate":"2021-04-13","value":0.005,"currency":"AUD"},{"executeDate":"2021-09-03","recordDate":"2021-09-06","paymentDate":"2021-09-13","value":0.005,"currency":"AUD"},{"executeDate":"2022-04-04","recordDate":"2022-04-05","paymentDate":"2022-04-12","value":0.005,"currency":"AUD"},{"executeDate":"2022-09-02","recordDate":"2022-09-05","paymentDate":"2022-09-12","value":0.005,"currency":"AUD"}]}}